title: Can the "right" EGFR-specific mAb dramatically improve EGFR-targeted therapy?
abstract: EGF receptor (EGFR)-specific monoclonal antibodies (mAb) display limited therapeutic efficacy in EGFR-positive solid tumors. To overcome this limitation, the significant improvement of the antibody-dependent cell-mediated cytotoxicity-mediated antitumor activity of a novel EGFR-specific mAb is described. Its potential impact on the efficacy of immunotherapy for EGFR-positive solid tumors is discussed.
authors: Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA.
authors: Francesco
authors: F
authors: Sabbatino
authors: Soldano
authors: S
authors: Ferrone
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000920:Antibody-Dependent Cell Cytotoxicity; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000276:immunology / Q000378:metabolism; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*
chemical_list: D000911:Antibodies, Monoclonal; D047428:Protein Kinase Inhibitors; D066246:ErbB Receptors